HC Wainwright Reiterates Buy Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They presently have a $32.00 price objective on the stock. HC Wainwright’s target price suggests a potential upside of 94.06% from the company’s current price.

Several other equities research analysts have also recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research report on Wednesday, November 6th. JMP Securities reissued a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a research report on Monday, November 4th. Lifesci Capital upgraded Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, StockNews.com raised Kura Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $28.83.

Kura Oncology Stock Performance

Shares of KURA stock opened at $16.49 on Wednesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a 52 week low of $8.80 and a 52 week high of $24.17. The company’s 50 day moving average price is $18.57 and its two-hundred day moving average price is $19.95. The company has a market capitalization of $1.28 billion, a P/E ratio of -6.99 and a beta of 0.86.

Institutional Trading of Kura Oncology

A number of large investors have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Kura Oncology in the 3rd quarter valued at about $25,000. SG Americas Securities LLC bought a new stake in Kura Oncology in the first quarter valued at approximately $110,000. Quarry LP acquired a new stake in shares of Kura Oncology in the second quarter valued at approximately $196,000. Entropy Technologies LP bought a new position in shares of Kura Oncology during the 1st quarter worth approximately $218,000. Finally, Erste Asset Management GmbH acquired a new position in shares of Kura Oncology during the 3rd quarter worth approximately $215,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.